Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$448K Buy
1,370
+10
+0.7% +$3.17K 0.14% 38
2025
Q3
$384K Sell
1,360
-49
-3% -$14.2K 0.13% 45
2025
Q2
$393K Buy
1,409
+12
+0.9% +$3.4K 0.09% 75
2025
Q1
$435K Buy
1,397
+7
+0.5% +$2.07K 0.11% 61
2024
Q4
$362K Hold
1,390
0.09% 76
2024
Q3
$448K Hold
1,390
0.11% 60
2024
Q2
$434K Hold
1,390
0.12% 54
2024
Q1
$395K Hold
1,390
0.12% 58
2023
Q4
$400K Sell
1,390
-10
-0.7% -$2.73K 0.14% 53
2023
Q3
$376K Buy
1,400
+10
+0.7% +$2.5K 0.15% 50
2023
Q2
$309K Hold
1,390
0.12% 59
2023
Q1
$336K Hold
1,390
0.2% 57
2022
Q4
$365K Hold
1,390
0.24% 50
2022
Q3
$313K Hold
1,390
0.28% 54
2022
Q2
$338K Hold
1,390
0.28% 45
2022
Q1
$336K Sell
1,390
-4
-0.3% -$919 0.27% 52
2021
Q4
$314K Buy
+1,394
New +$294K 0.26% 64

Other funds holding AMGN

Stephens Consulting's AMGN Position: Q4 2025 in Review

Stephens Consulting increased its Amgen (AMGN) stake by 0.74% in Q4 2025, buying an estimated $3.17K and bringing the position to 1,370 shares worth $448K. The position accounts for 0.14% of the portfolio, ranked #38.

Stephens Consulting first reported a position in AMGN in Q4 2021 and has held it in 17 quarters since. 3,084 funds tracked by Wall St. Rank hold AMGN as of Q4 2025.

  • Stephens Consulting held 1,370 shares of Amgen worth $448K as of Q4 2025.
  • Stephens Consulting bought 10 Amgen shares in Q4 2025, an estimated $3.17K.
  • Amgen made up 0.14% of Stephens Consulting's portfolio in Q4 2025, its #38 holding.
  • Stephens Consulting first reported a position in Amgen in Q4 2021 and has held it in 17 quarters since.
  • 3,084 funds tracked by Wall St. Rank held Amgen as of Q4 2025.

Based on Stephens Consulting's 13F filing for Q4 2025, filed 13 Jan 2026.